Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4666069 | 0.89 | MAP2 (0.48) | MAP2ALDH1A1KDM4EFOLH1EGFR | |
| SCHEMBL631701 | 0.85 | MAP2 (0.53) | MAP2ALDH1A1KDM4EFOLH1EGFR | |
| SCHEMBL2983431 | 0.84 | MAP2 (0.51) | MAP2ALDH1A1KDM4EFOLH1EGFR | |
| SCHEMBL4042667 | 0.83 | MAP2 (0.46) | MAP2ALDH1A1KDM4EFOLH1EGFR | |
| SCHEMBL4614532 | 0.81 | MAP2 (0.52) | MAP2KDM4E | |
| SCHEMBL4640371 | 0.81 | MAP2 (0.43) | MAP2EGFR | |
| SCHEMBL3583092 | 0.80 | MAP2 (0.48) | MAP2ALDH1A1KDM4EFOLH1EGFR | |
| SCHEMBL5279031 | 0.80 | MAP2 (0.57) | MAP2ALDH1A1KDM4EFOLH1EGFR | |
| SCHEMBL28746390 | 0.78 | MCL1 (0.57) | MAP2ALDH1A1KDM4EFOLH1EGFR | |
| SCHEMBL4642042 | 0.78 | FEN1 (0.37) | MAP2ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075987-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | claimed |
| EP-2019102-A1 | Alkylacetylene substituted Acyltryptophanols | Bayer Schering Pharma AG (DE) | 2009-01-28 | — | — | EP | claimed |
| US-20080255117-A1 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-10-16 | — | — | US | claimed |
| US-20080221195-A1 | 1,2-DIARYLACETYLENE DERIVATIVES OF ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-09-11 | — | — | US | claimed |
| EP-1964834-A1 | Sulphonyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | claimed |
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-08-28 | — | — | US | claimed |
| EP-1956016-A1 | Bicyclic acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-08-13 | — | — | EP | claimed |
| WO-2008071455-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | claimed |
| EP-1932831-A1 | 1,2-Diarylacetylene Derivatives of Acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-06-18 | — | — | EP | claimed |
| EP-1912970-A2 | ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-23 | — | — | EP | claimed |
| US-20070060573-A1 | Acyltryptophanols | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | claimed |
| WO-2007017289-A2 | ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | WO | claimed |
| US-20090075987-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| EP-2019102-A1 | Alkylacetylene substituted Acyltryptophanols | Bayer Schering Pharma AG (DE) | 2009-01-28 | — | — | EP | disclosed |
| US-20080255117-A1 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080221195-A1 | 1,2-DIARYLACETYLENE DERIVATIVES OF ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-09-11 | — | — | US | disclosed |
| EP-1932831-A1 | 1,2-Diarylacetylene Derivatives of Acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-06-18 | — | — | EP | disclosed |
| EP-1912970-A2 | ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-20070060573-A1 | Acyltryptophanols | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | disclosed |
| WO-2007017289-A2 | ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255117-A1 | SULFONYLTRYPTOPHANOLS | FSHR, NPY1R, GNRHR | MAP2 3047/4885ALDH1A1 4169/4885KDM4E 2544/4885 |
| US-20080221195-A1 | 1,2-DIARYLACETYLENE DERIVATIVES OF ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | MAP2 1870/4885ALDH1A1 2416/4885KDM4E 1229/4885 |
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | MAP2 1805/4885ALDH1A1 3513/4885KDM4E 2247/4885 |
| US-20070060573-A1 | Acyltryptophanols | FSHR, NPY1R, NPY2R | MAP2 2645/4885ALDH1A1 3830/4885KDM4E 2399/4885 |
| US-20090075987-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | FSHR, GNRHR, CYP19A1 | MAP2 1898/4885ALDH1A1 2364/4885KDM4E 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.